Total Payments
$69,991
2024 Payments
$43,501
Companies
9
Transactions
28
Medicare Patients
202
Medicare Billing
$26,716
Payment Breakdown by Category
Research$46,147 (65.9%)
Consulting$13,084 (18.7%)
Travel$8,414 (12.0%)
Other$1,751 (2.5%)
Food & Beverage$595.47 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $46,147 | 5 | 65.9% |
| Consulting Fee | $13,084 | 5 | 18.7% |
| Travel and Lodging | $8,414 | 8 | 12.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,751 | 2 | 2.5% |
| Food and Beverage | $595.47 | 8 | 0.9% |
Payments by Type
Research
$46,147
5 transactions
General
$23,844
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| IGI Inc | $40,769 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $8,463 | 8 | $0 (2021) |
| Eli Lilly and Company | $8,195 | 6 | $0 (2019) |
| F. Hoffmann-La Roche AG | $6,740 | 5 | $0 (2021) |
| Telix Pharmaceuticals | $2,667 | 3 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $2,584 | 1 | $0 (2020) |
| Novocure Inc. | $457.60 | 2 | $0 (2017) |
| MACROGENICS, INC. | $65.14 | 1 | $0 (2024) |
| Puma Biotechnology, Inc. | $49.77 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,501 | 5 | IGI Inc ($40,769) |
| 2021 | $6,186 | 2 | F. Hoffmann-La Roche AG ($3,686) |
| 2020 | $9,537 | 5 | Merck Sharp & Dohme Corporation ($5,650) |
| 2019 | $9,800 | 12 | Eli Lilly and Company ($7,806) |
| 2017 | $966.90 | 4 | Novocure Inc. ($457.60) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | IGI Inc | — | — | Cash or cash equivalent | $40,769.00 | Research |
| Study: GRC 54276-101 | ||||||
| 06/02/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $167.07 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 06/01/2024 | MACROGENICS, INC. | MARGENZA (Drug) | Food and Beverage | In-kind items and services | $65.14 | General |
| Category: Oncology | ||||||
| 03/19/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 01/03/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $3,685.54 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST CANCER • Category: BioOncology | ||||||
| 02/10/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: ONCOLOGY | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $817.78 | Research |
| Study: PATRICIA • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $485.56 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST CANCER • Category: BioOncology | ||||||
| 08/31/2020 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,584.00 | General |
| 01/29/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| 01/29/2020 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 12/31/2019 | F. Hoffmann-La Roche AG | Perjeta (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,258.87 | General |
| Category: BioOncology | ||||||
| 12/11/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Food and Beverage | In-kind items and services | $49.77 | General |
| Category: Oncology | ||||||
| 11/21/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $64.41 | General |
| 11/21/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 11/21/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $48.58 | General |
| 11/21/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 10/02/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $235.12 | General |
| 10/02/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $91.84 | General |
| 09/30/2019 | F. Hoffmann-La Roche AG | Perjeta (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $492.22 | General |
| Category: BioOncology | ||||||
| 09/28/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $241.88 | General |
| 09/27/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $7,130.43 | General |
| 09/27/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $106.84 | General |
| 07/26/2017 | Eli Lilly and Company | — | — | In-kind items and services | $388.80 | Research |
| Study: A PHASE 2 STUDY OF ABEMACICLIB IN PATIENTS WITH BRAIN METASTASES SECONDARY TO HORMONE RECEPTOR POSITIVE BREAST CANCER, NON-SMALL CELL LUNG CANCER, OR MELANOMA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GRC 54276-101 | IGI Inc | $40,769 | 1 |
| AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST CANCER | F. Hoffmann-La Roche AG | $4,171 | 2 |
| PATRICIA | F. Hoffmann-La Roche AG | $817.78 | 1 |
| A PHASE 2 STUDY OF ABEMACICLIB IN PATIENTS WITH BRAIN METASTASES SECONDARY TO HORMONE RECEPTOR POSITIVE BREAST CANCER, NON-SMALL CELL LUNG CANCER, OR MELANOMA | Eli Lilly and Company | $388.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 14 | 26 | $10,946 | $3,320 |
| 2021 | 2 | 53 | 77 | $14,261 | $7,667 |
| 2020 | 4 | 135 | 186 | $38,152 | $15,729 |
Total Patients
202
Total Services
289
Medicare Billing
$26,716
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 14 | 26 | $10,946 | $3,320 | 30.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 28 | 40 | $8,600 | $4,752 | 55.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 25 | 37 | $5,661 | $2,915 | 51.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 45 | 67 | $14,405 | $5,840 | 40.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 49 | 78 | $11,934 | $4,958 | 41.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $9,425 | $3,917 | 41.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 12 | 12 | $2,388 | $1,014 | 42.5% |
About Dr. Solmaz Sahebjam, MD
Dr. Solmaz Sahebjam, MD is a Internal Medicine healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/14/2008. The National Provider Identifier (NPI) number assigned to this provider is 1821265232.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Solmaz Sahebjam, MD has received a total of $69,991 in payments from pharmaceutical and medical device companies, with $43,501 received in 2024. These payments were reported across 28 transactions from 9 companies. The most common payment nature is "" ($46,147).
As a Medicare-enrolled provider, Sahebjam has provided services to 202 Medicare beneficiaries, totaling 289 services with total Medicare billing of $26,716. Data is available for 3 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology, Medical Oncology
- Location Washington, DC
- Active Since 05/14/2008
- Last Updated 05/14/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1821265232
Products in Payments
- Perjeta (Biological) $6,740
- ILLUCCIX (Drug) $2,667
- KEYTRUDA (Biological) $2,621
- Optune (Device) $457.60
- MARGENZA (Drug) $65.14
- Nerlynx (Drug) $49.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Washington
Lawrence Dubuske, M.d, M.D
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Kavita Patel, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Andrea Singer
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Theo Hodge, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Ashte Collins, M.d, M.D
Internal Medicine — Payments: $837,513
Internal Medicine $837,513
Manish Shah, Md, MD
Internal Medicine — Payments: $456,731
Internal Medicine $456,731